News & events Upcoming events Nov 29, 2022 - Dec 2, 2022 CTAD 2022 - 15th Clinical Trials on Alzheimer's Disease Congress San Francisco, United States of America More info and meet us there Dec 7, 2022 - Dec 8, 2022 Congrès des Unités de Soins Alzheimer - USPALZ 2022 Issy-les-Moulineaux (Paris), France More info and meet us there Feb 6, 2023 - Feb 9, 2023 Medlab Middle East 2023 Dubai, United Arab Emirates More info and meet us there See all upcoming events Latest news Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Load More
Nov 29, 2022 - Dec 2, 2022 CTAD 2022 - 15th Clinical Trials on Alzheimer's Disease Congress San Francisco, United States of America More info and meet us there
Dec 7, 2022 - Dec 8, 2022 Congrès des Unités de Soins Alzheimer - USPALZ 2022 Issy-les-Moulineaux (Paris), France More info and meet us there
Feb 6, 2023 - Feb 9, 2023 Medlab Middle East 2023 Dubai, United Arab Emirates More info and meet us there
Oct 11, 2022 Fujirebio Europe receives distribution rights to market Self-screen's PreCursor-M+ methylation-specific molecular assay, a powerful solution to identify women at high risk for cervical cancer Gent, Belgium and Amsterdam, The Netherlands – October 11, 2022: Fujirebio Europe and Self-screen B.V. today announce a commercial... Read more
Jun 23, 2022 Fujirebio acquires ADx NeuroSciences and confirms its intentions to bring better and earlier neurodegenerative disease diagnostic solutions to the global diagnostics industry Gent, Belgium and Tokyo, Japan, June 23, 2022 – H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx... Read more
May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more
Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more
Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more
Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
